{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:11:30Z","timestamp":1793725890758,"version":"4.6.1"},"reference-count":128,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>COVID-19 is associated with endothelial activation in the setting of a potent inflammatory reaction and a hypercoagulable state. The end result of this thromboinflammatory state is an excess in thrombotic events, in particular venous thromboembolism. Pulmonary embolism (PE) has been of special interest in patients with COVID-19 given its association with respiratory deterioration, increased risk of intensive care unit admission, and prolonged hospital stay. The pathophysiology and clinical characteristics of COVID-19-associated PE may differ from the conventional non\u2013COVID-19-associated PE. In addition to embolic events from deep vein thrombi, in situ pulmonary thrombosis, particularly in smaller vascular beds, may be relevant in patients with COVID-19. Appropriate prevention of thrombotic events in COVID-19 has therefore become of critical interest. Several changes in viral biology, vaccination, and treatment management during the pandemic may have resulted in changes in incidence trends. This review provides an overview of the pathophysiology, epidemiology, clinical characteristics, and risk factors of COVID-19-associated PE. Furthermore, we briefly summarize the results from randomized controlled trials of preventive antithrombotic therapies in COVID-19, focusing on their findings related to PE. We discuss the acute treatment of COVID-19-associated PE, which is substantially similar to the management of conventional non-COVID-19 PE. Ultimately, we comment on the current knowledge gaps in the evidence and the future directions in the treatment and follow-up of COVID-19-associated PE, including long-term management, and its possible association with long-COVID.<\/jats:p>","DOI":"10.1055\/s-0042-1757634","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T18:59:56Z","timestamp":1665601196000},"page":"816-832","source":"Crossref","is-referenced-by-count":39,"title":["COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment"],"prefix":"10.1055","volume":"49","author":[{"given":"Luis","family":"Ortega-Paz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita H.","family":"Talasaz","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Sadeghipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana S.","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert D.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jara-Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sholzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"e019650","DOI":"10.1161\/JAHA.120.019650","article-title":"Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management","volume":"10","author":"L Ortega-Paz","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"23","key":"ref2","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.jacc.2020.04.031","article-title":"COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review","volume":"75","author":"B Bikdeli","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0041-1736166","article-title":"The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19","volume":"48","author":"M Bahraini","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1055\/s-0040-1718532","article-title":"Venous thromboembolism in COVID-19","volume":"120","author":"S Schulman","year":"2020","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1055\/s-0040-1715798","article-title":"Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology\/Vascular Medicine","volume":"120","author":"G T Gerotziafas","year":"2020","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1055\/a-1535-8807","article-title":"The COVID-19 pandemic and the need for an integrated and equitable approach: an international expert consensus paper","volume":"121","author":"G T Gerotziafas","year":"2021","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1055\/s-0040-1713152","article-title":"Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research","volume":"120","author":"B Bikdeli","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Z Varga","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3390\/jcm10102096","article-title":"Myocardial injury in COVID-19 patients: association with inflammation, coagulopathy and in-hospital prognosis","volume":"10","author":"V Ar\u00e9valos","year":"2021","journal-title":"J Clin Med"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-0041-1732372","article-title":"Involvement of inflammation in venous thromboembolic disease: an update in the age of COVID-19","volume":"48","author":"P Poredos","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1055\/s-0040-1718735","article-title":"Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19","volume":"120","author":"S Gencer","year":"2020","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref12","first-page":"128","article-title":"Acute and chronic effects of COVID-19 on the cardiovascular system","volume":"8","author":"V Ar\u00e9valos","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"issue":"15","key":"ref13","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.jacc.2021.02.035","article-title":"Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC state-of-the-art review","volume":"77","author":"A H Talasaz","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1055\/a-1499-0119","article-title":"SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia","volume":"121","author":"I Elalamy","year":"2021","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19","volume":"383","author":"M Ackermann","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1473-3099(20)30434-5","article-title":"Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study","volume":"20","author":"L Carsana","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"08","key":"ref17","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1055\/a-1366-9656","article-title":"Prevalence and predictors of venous thromboembolism or mortality in hospitalized COVID-19 patients","volume":"121","author":"S L Cohen","year":"2021","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1055\/a-1692-9939","article-title":"Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19: a multicenter observational study","volume":"122","author":"R Cangemi","year":"2022","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S2665-9913(20)30121-1","article-title":"Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia","volume":"2","author":"D McGonagle","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"32","key":"ref20","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/eurheartj\/ehaa623","article-title":"COVID-19 is, in the end, an endothelial disease","volume":"41","author":"P Libby","year":"2020","journal-title":"Eur Heart J"},{"issue":"07","key":"ref21","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jth.14850","article-title":"Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis","volume":"18","author":"M Panigada","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref22","first-page":"CD013879","article-title":"COVID-19 and its cardiovascular effects: a systematic review of prevalence studies","volume":"3","author":"P Pellicori","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.chest.2020.11.005","article-title":"Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis","volume":"159","author":"D Jim\u00e9nez","year":"2021","journal-title":"Chest"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/rth2.12439","article-title":"Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis","volume":"4","author":"S Nopp","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"04","key":"ref25","first-page":"163","article-title":"Systematic screening for a proximal DVT in COVID-19 hospitalized patients: results of a comparative study","volume":"46","author":"Y Fares","year":"2021","journal-title":"J Med Vasc"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"624808","DOI":"10.3389\/fmed.2020.624808","article-title":"Systematic screening for deep vein thrombosis in critically ill inpatients with COVID-19: impact on the incidence of venous thromboembolism","volume":"7","author":"F X Lap\u00e9bie","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref27","first-page":"pvab070","article-title":"Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","author":"L Ortega-Paz","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1093\/ehjcvp\/pvac010","article-title":"Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19","volume":"8","author":"L Ortega-Paz","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"e29721","DOI":"10.1002\/pbc.29721","article-title":"Pulmonary embolism in pediatric and adolescent patients with COVID-19 infection during the SARS-CoV-2 delta wave","volume":"69","author":"C T Cohen","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10140-022-02039-z","article-title":"Incidence of pulmonary embolism in COVID-19 infection in the ED: ancestral, delta, omicron variants and vaccines","volume":"29","author":"N Law","year":"2022","journal-title":"Emerg Radiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e069590","DOI":"10.1136\/bmj-2021-069590","article-title":"Risks of deep vein thrombosis, pulmonary embolism, and bleeding after COVID-19: nationwide self-controlled cases series and matched cohort study","volume":"377","author":"I Katsoularis","year":"2022","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.thromres.2020.12.019","article-title":"Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave","volume":"199","author":"F HJ Kaptein","year":"2021","journal-title":"Thromb Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"N Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13613-020-00741-0","article-title":"Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review","volume":"10","author":"Y Sakr","year":"2020","journal-title":"Ann Intensive Care"},{"issue":"06","key":"ref36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","volume":"46","author":"J Helms","year":"2020","journal-title":"Intensive Care Med"},{"issue":"32","key":"ref37","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/eurheartj\/ehaa500","article-title":"Pulmonary embolism in COVID-19 patients: a French multicentre cohort study","volume":"41","author":"C Fauvel","year":"2020","journal-title":"Eur Heart J"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"F A Klok","year":"2020","journal-title":"Thromb Res"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/jama.2020.13372","article-title":"Thrombosis in hospitalized patients with COVID-19 in a New York City health system","volume":"324","author":"S Bilaloglu","year":"2020","journal-title":"JAMA"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2021.11.029","article-title":"Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: a systematic review and meta-analysis","volume":"209","author":"M Zuin","year":"2022","journal-title":"Thromb Res"},{"issue":"17","key":"ref41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B Randomized Clinical Trial","volume":"326","author":"J M Connors","year":"2021","journal-title":"JAMA"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1093\/cid\/ciab813","article-title":"Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019","volume":"75","author":"J Ananworanich","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.thromres.2020.10.022","article-title":"In situ pulmonary thrombosis in patients with COVID-19 pneumonia: different phenotypes may exist","volume":"196","author":"L Wang","year":"2020","journal-title":"Thromb Res"},{"issue":"33","key":"ref44","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/eurheartj\/ehab314","article-title":"Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome","volume":"42","author":"\u00d2 Mir\u00f3","year":"2021","journal-title":"Eur Heart J"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1160\/TH17-07-0511","article-title":"Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE)","volume":"118","author":"B Bikdeli","year":"2018","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1718402","article-title":"Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19","volume":"47","author":"C Fern\u00e1ndez-Capit\u00e1n","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.1148\/radiol.2020203557","article-title":"Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis","volume":"298","author":"Y J Suh","year":"2021","journal-title":"Radiology"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0041-1740152","article-title":"Pulmonary embolism in patients with COVID-19: comparison between different care settings","volume":"49","author":"G Buso","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"ref49","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1111\/jth.15533","article-title":"Use of novel antithrombotic agents for COVID-19: systematic summary of ongoing randomized controlled trials","volume":"19","author":"A H Talasaz","year":"2021","journal-title":"J Thromb Haemost"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2020.06.010","article-title":"Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease?","volume":"193","author":"L F van Dam","year":"2020","journal-title":"Thromb Res"},{"issue":"04","key":"ref51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study","volume":"173","author":"D Wichmann","year":"2020","journal-title":"Ann Intern Med"},{"issue":"02","key":"ref52","doi-asserted-by":"crossref","first-page":"2002964","DOI":"10.1183\/13993003.02964-2020","article-title":"Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis","volume":"59","author":"V Bellou","year":"2022","journal-title":"Eur Respir J"},{"issue":"04","key":"ref53","first-page":"330","article-title":"Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews","volume":"7","author":"S L Harrison","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"236","key":"ref54","first-page":"n236","article-title":"Update to living systematic review on prediction models for diagnosis and prognosis of COVID-19","volume":"372","year":"2021","journal-title":"BMJ"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"m3339","DOI":"10.1136\/bmj.m3339","article-title":"Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score","volume":"370","author":"S R Knight","year":"2020","journal-title":"BMJ"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/thoraxjnl-2021-217629","article-title":"Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol","volume":"77","author":"S R Knight","year":"2022","journal-title":"Thorax"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"16025","DOI":"10.1038\/s41598-021-95512-7","article-title":"Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis","volume":"11","author":"C A G\u00f3mez","year":"2021","journal-title":"Sci Rep"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejim.2022.01.035","article-title":"Pulmonary embolism severity and in-hospital mortality: an international comparative study between COVID-19 and non-COVID patients","volume":"98","author":"\u00d2 Mir\u00f3","year":"2022","journal-title":"Eur J Intern Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis","volume":"29","author":"M B Malas","year":"2020","journal-title":"EClinicalMedicine"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2022.03.017","article-title":"Venous thromboembolism in patients hospitalised with COVID-19 in England","volume":"213","author":"L N Roberts","year":"2022","journal-title":"Thromb Res"},{"issue":"18","key":"ref61","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"E Driggin","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1055\/s-0042-1744302","article-title":"To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years","volume":"49","author":"J G Rizk","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1111\/jth.15094","article-title":"Anticoagulant interventions in hospitalized patients with COVID-19: a scoping review of randomized controlled trials and call for international collaboration","volume":"18","author":"T Tritschler","year":"2020","journal-title":"J Thromb Haemost"},{"key":"ref64","first-page":"CD013739","article-title":"Prophylactic anticoagulants for people hospitalised with COVID-19","volume":"10","author":"R L Flumignan","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"09","key":"ref65","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.cjca.2021.05.009","article-title":"Challenges and lessons learned from COVID-19 trials: Should we be doing clinical trials differently?","volume":"37","author":"P Janiaud","year":"2021","journal-title":"Can J Cardiol"},{"issue":"08","key":"ref66","doi-asserted-by":"crossref","first-page":"e12638","DOI":"10.1002\/rth2.12638","article-title":"Randomized trials of therapeutic heparin for COVID-19: a meta-analysis","volume":"5","author":"M Sholzberg","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"08","key":"ref67","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1055\/s-0040-1716874","article-title":"Sulodexide versus control and the risk of thrombotic and hemorrhagic events: meta-analysis of randomized trials","volume":"46","author":"B Bikdeli","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref68","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1055\/a-1414-5216","article-title":"Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial","volume":"121","author":"A J Gonzalez-Ochoa","year":"2021","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref69","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2352-3026(22)00173-9","article-title":"Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial","volume":"9","author":"F Cools","year":"2022","journal-title":"Lancet Haematol"},{"issue":"08","key":"ref70","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(22)00175-2","article-title":"Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"9","author":"S Barco","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2021.02.001","article-title":"Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: the PREVENT-HD study","volume":"235","author":"W H Capell","year":"2021","journal-title":"Am Heart J"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"R D Lopes","year":"2021","journal-title":"Lancet"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/a-1667-7534","article-title":"Therapeutic versus prophylactic bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP Study): an open-label, multicenter, randomized, controlled trial","volume":"122","author":"M Marcos-Jubilar","year":"2022","journal-title":"Thromb Haemost"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with COVID-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"M Sholzberg","year":"2021","journal-title":"BMJ"},{"issue":"05","key":"ref75","doi-asserted-by":"crossref","first-page":"e13735","DOI":"10.1111\/eci.13735","article-title":"Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: the X-COVID-19 Randomized Trial","volume":"52","author":"N Morici","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"09","key":"ref76","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19","volume":"385","author":"P R Lawler","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref77","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","article-title":"Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID Randomized Clinical Trial","volume":"181","author":"A C Spyropoulos","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"09","key":"ref78","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jacc.2021.12.023","article-title":"Anticoagulation in patients with COVID-19: JACC review topic of the week","volume":"79","author":"M E Farkouh","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID)","volume":"196","author":"A CB Lemos","year":"2020","journal-title":"Thromb Res"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1055\/a-1485-2372","article-title":"Intermediate-dose versus standard-dose prophylactic anticoagulation in patients with COVID-19 admitted to the intensive care unit: 90-day results from the INSPIRATION Randomized Trial","volume":"122","author":"B Bikdeli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"16","key":"ref81","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","article-title":"Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION Randomized Clinical Trial","volume":"325","author":"P Sadeghipour","year":"2021","journal-title":"JAMA"},{"issue":"09","key":"ref82","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/jth.15450","article-title":"Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial","volume":"19","author":"U S Perepu","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref83","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1002\/rth2.12712","article-title":"Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: the Swiss COVID-HEP randomized clinical trial","volume":"6","author":"M Blondon","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"09","key":"ref84","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with COVID-19","volume":"385","author":"E C Goligher","year":"2021","journal-title":"N Engl J Med"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"E Ramacciotti","year":"2022","journal-title":"Lancet"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"R C Group","year":"2022","journal-title":"Lancet"},{"issue":"13","key":"ref87","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: a randomized clinical trial","volume":"327","author":"C A Bradbury","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"ref89","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref90","first-page":"e068407","article-title":"Atorvastatin versus placebo in patients with COVID-19 in intensive care: randomized controlled trial","volume":"376","author":"INSPIRATION-S Investigators","year":"2022","journal-title":"BMJ"},{"issue":"19","key":"ref91","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19 - final report","volume":"383","author":"J H Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"03","key":"ref92","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial","volume":"326","author":"R Caricchio","year":"2021","journal-title":"JAMA"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"A Cuker","year":"2021","journal-title":"Blood Adv"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.chest.2022.02.006","article-title":"Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report","volume":"162","author":"L K Moores","year":"2022","journal-title":"Chest"},{"issue":"10","key":"ref96","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/jth.15808","article-title":"ISTH guidelines for antithrombotic treatment in COVID-19","volume":"20","author":"S Schulman","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref97","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s11239-021-02504-5","article-title":"External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19","volume":"52","author":"M Goldin","year":"2021","journal-title":"J Thromb Thrombolysis"},{"issue":"04","key":"ref98","doi-asserted-by":"crossref","first-page":"2001811","DOI":"10.1183\/13993003.01811-2020","article-title":"Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients","volume":"56","author":"B Mouhat","year":"2020","journal-title":"Eur Respir J"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"109336","DOI":"10.1016\/j.ejrad.2020.109336","article-title":"Pulmonary thromboembolic disease in COVID-19 patients on CT pulmonary angiography - prevalence, pattern of disease and relationship to D-dimer","volume":"132","author":"M WX Ooi","year":"2020","journal-title":"Eur J Radiol"},{"issue":"06","key":"ref100","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3390\/diagnostics12061350","article-title":"Diagnostic management of acute pulmonary embolism in COVID-19 and other special patient populations","volume":"12","author":"E SL Martens","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijid.2021.11.038","article-title":"Predictive scores for the diagnosis of pulmonary embolism in COVID-19: a systematic review","volume":"115","author":"L V Rindi","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"02","key":"ref102","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jinf.2021.01.003","article-title":"Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection","volume":"82","author":"A Garc\u00eda-Ortega","year":"2021","journal-title":"J Infect"},{"issue":"06","key":"ref103","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1016\/j.chest.2020.08.2064","article-title":"Diagnosis and treatment of pulmonary embolism during the coronavirus disease 2019 pandemic: a position paper from the National PERT Consortium","volume":"158","author":"R P Rosovsky","year":"2020","journal-title":"Chest"},{"issue":"02","key":"ref104","doi-asserted-by":"crossref","first-page":"ytaa522","DOI":"10.1093\/ehjcr\/ytaa522","article-title":"Acute pulmonary embolism and systemic thrombolysis in the era of COVID-19 global pandemic 2020: a case series of seven patients admitted to a regional hospital in the French epidemic cluster","volume":"5","author":"J Philippe","year":"2021","journal-title":"Eur Heart J Case Rep"},{"issue":"04","key":"ref105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"S V Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2021.12.003","article-title":"Tissue plasminogen activator for the treatment of adults with critical COVID-19: a pilot randomized clinical trial","volume":"216","author":"F Rashidi","year":"2022","journal-title":"Thromb Res"},{"issue":"01","key":"ref107","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.chest.2022.03.043","article-title":"No VTE recurrence after 1-year follow-up of hospitalized patients with COVID-19 and a VTE event: a prospective study","volume":"162","author":"M Delrue","year":"2022","journal-title":"Chest"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study","volume":"399","author":"N Wolter","year":"2022","journal-title":"Lancet"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis","volume":"114","author":"C Zheng","year":"2022","journal-title":"Int J Infect Dis"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"n1114","DOI":"10.1136\/bmj.n1114","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"A Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"issue":"01","key":"ref112","doi-asserted-by":"crossref","first-page":"rkaa081","DOI":"10.1093\/rap\/rkaa081","article-title":"Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots","volume":"5","author":"M L Tung","year":"2021","journal-title":"Rheumatol Adv Pract"},{"issue":"01","key":"ref113","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0041-1728832","article-title":"COVID-19 and antiphospholipid antibodies: Time for a reality check?","volume":"48","author":"E J Favaloro","year":"2022","journal-title":"Semin Thromb Hemost"},{"key":"ref114","first-page":"CD005258","article-title":"Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism","volume":"1","author":"S Kakkos","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"01","key":"ref115","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s13054-020-03273-y","article-title":"Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations","volume":"24","author":"A Flaczyk","year":"2020","journal-title":"Crit Care"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.thromres.2021.10.010","article-title":"Comparison of clinical outcomes using activated partial thromboplastin time versus antifactor-Xa for monitoring therapeutic unfractionated heparin: a systematic review and meta-analysis","volume":"208","author":"R Swayngim","year":"2021","journal-title":"Thromb Res"},{"issue":"06","key":"ref118","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0022-2143(97)90115-3","article-title":"The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance","volume":"130","author":"L Manson","year":"1997","journal-title":"J Lab Clin Med"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"issue":"05","key":"ref120","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with COVID-19 pneumonia","volume":"385","author":"P O Guimar\u00e3es","year":"2021","journal-title":"N Engl J Med"},{"issue":"08","key":"ref121","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19","volume":"384","author":"P Horby","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"ref122","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with COVID-19","volume":"384","author":"A C Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2020.05.007","article-title":"Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: thinking beyond the guidelines","volume":"192","author":"S D Qanadli","year":"2020","journal-title":"Thromb Res"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2022.05.011","article-title":"Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: rationale and design of the HI-PEITHO study","volume":"251","author":"F A Klok","year":"2022","journal-title":"Am Heart J"},{"issue":"01","key":"ref125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.medcli.2021.05.006","article-title":"Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes","volume":"158","author":"V Arevalos","year":"2022","journal-title":"Med Clin (Barc)"},{"issue":"07","key":"ref126","doi-asserted-by":"crossref","first-page":"e0255263","DOI":"10.1371\/journal.pone.0255263","article-title":"Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: a structured summary of a study protocol","volume":"16","author":"V Ar\u00e9valos","year":"2021","journal-title":"PLoS One"},{"issue":"03","key":"ref127","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-022-01689-3","article-title":"Long-term cardiovascular outcomes of COVID-19","volume":"28","author":"Y Xie","year":"2022","journal-title":"Nat Med"},{"issue":"04","key":"ref128","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus","volume":"22","author":"J B Soriano","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"15","key":"ref129","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/jama.2021.3331","article-title":"Four-month clinical status of a cohort of patients after hospitalization for COVID-19","volume":"325","author":"L Morin","year":"2021","journal-title":"JAMA"},{"issue":"06","key":"ref130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/jama.2022.0040","article-title":"Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19","volume":"327","author":"H Heesakkers","year":"2022","journal-title":"JAMA"},{"issue":"04","key":"ref131","doi-asserted-by":"crossref","first-page":"00431","DOI":"10.1183\/23120541.00431-2021","article-title":"Rising COVID-19 related acute pulmonary emboli but falling national chronic thromboembolic pulmonary hypertension referrals from a large national dataset","volume":"7","author":"J Newman","year":"2021","journal-title":"ERJ Open Res"},{"issue":"06","key":"ref132","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"S M Stevens","year":"2021","journal-title":"Chest"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1757634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T07:47:44Z","timestamp":1717746464000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1757634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":128,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2023,10,19]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1757634","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}